Akèy › Maladi Crohn › Texas › Lubbock
Etid klinik pou Maladi Crohn nan Lubbock, TX
10 etid pou Maladi Crohn ap chèche patisipan nan sit nan ak bò kote Lubbock (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)
Ap rekriteFaz 3
- GI Alliance - Lubbock ( Site 0288), Lubbock
- Caprock Gastro Research ( Site 0293), Lubbock
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
Ap rekriteFaz 3
- Caprock Gastro Research ( Site 5077), Lubbock
Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
Ap rekriteFaz 2
- GI Alliance - Lubbock /ID# 283920, Lubbock
- Caprock Gastro Research - Lubbock /ID# 283921, Lubbock
A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
Ap rekriteFaz 4
- West Texas Research Institute, Lubbock
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
Ap rekriteFaz 2
- Caprock Gastro Research - Lubbock /ID# 265541, Lubbock
A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
Ap rekriteFaz 3
- Lubbock Gastroenterology, Lubbock
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
Ap rekriteFaz 3
- GI Alliance - Lubbock-Site Number: 8400092, Lubbock
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
Ap rekriteFaz 3
- GI Alliance - Lubbock-Site Number: 8400092, Lubbock
A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
Ap rekriteFaz 4
- Texas Digestive Disease Consultants Lubbock, Lubbock
A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
Ap rekriteFaz 2
- Mirador Therapeutics Selected Site, Lubbock
Etid Maladi Crohn nan lòt vil
- New York City, NY35 etid
- Cleveland, OH19 etid
- St. Louis, MO19 etid
- Boston, MA19 etid
- Miami, FL19 etid
- Orlando, FL17 etid
- Houston, TX17 etid
- Atlanta, GA17 etid
- Tyler, TX16 etid
- San Diego, CA15 etid
- San Antonio, TX15 etid
- Los Angeles, CA15 etid
Lòt etid nan Lubbock
- Kolit Ulseratif9 etid
- Kansè nan tete6 etid
- Kansè Poumon ki pa ti selil4 etid
- Atrit psoryatik3 etid
- Akidan serebavaskilè3 etid
- Sipwa3 etid
- Obèsite3 etid
- Maladi Entestinal Anflamatwa3 etid
- Limfòm Burkitt3 etid
- Myelom Miltip3 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.